A rational targeted therapy for platinum-resistant small-cell lung cancer
- PMID: 33848475
- DOI: 10.1016/j.ccell.2021.03.003
A rational targeted therapy for platinum-resistant small-cell lung cancer
Abstract
Small-cell lung cancer (SCLC) is initially sensitive to platinum doublet chemotherapy, providing dramatic clinical benefit. Unfortunately, most SCLCs relapse and become resistant to further therapy. In this issue of Cancer Cell, Thomas et al. show that some platinum-resistant SCLCs benefit from combination therapy with topotecan plus the ATR (ataxia telangiectasia-mutated and rad3-related) inhibitor berzosertib.
Copyright © 2021. Published by Elsevier Inc.
Conflict of interest statement
Declaration of interests J.D.M. receives NCI and UT Southwestern licensing royalties for distribution of human tumor lines.
Comment on
-
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.Cancer Cell. 2021 Apr 12;39(4):566-579.e7. doi: 10.1016/j.ccell.2021.02.014. Cancer Cell. 2021. PMID: 33848478 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous